BV+CHP PROTOKOLÜ
Kaynaklar:
1- S Horwitz et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol . 2022 Mar;33(3):288-298.
1- S Horwitz et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol . 2022 Mar;33(3):288-298.